Pediatrics · LP-010
Salbutamol Syrup
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-010Pediatrics
- Generic identity
- SalbutamolSyrup
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-010
- Generic identity
- Salbutamol
- Presentation
- Syrup
- Catalogue strength
- 2 mg/5 mL
- Catalogue pack
- Bottle 60 mL / 100 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: salbutamol.
- Dosage form/route: oral syrup.
- Catalogue concentration: 2 mg/5 mL.
- Catalogue pack options: bottle 60 mL and bottle 100 mL.
- Catalogue category: Pediatrics; category is not age authorisation.
Layer 02 · Unresolved product-specific fields
- Exact salt/base expression and formulation composition.
- Approved age range, indication and dosing for oral use in the intended market.
- Measuring-device, shaking and administration instructions.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 2 mg/5 mL | Oral syrup | — | Bottle 60 mL | Oral product-specific formulation and authorised-use evidence required. |
| B | 2 mg/5 mL | Oral syrup | — | Bottle 100 mL | Oral product-specific formulation and authorised-use evidence required. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Salbutamol, called albuterol in the United States, is a short-acting bronchodilator that relaxes airway smooth muscle. Oral and inhaled presentations have materially different delivery characteristics and are not interchangeable by volume or stated strength. Inhaled formulations are used in respiratory treatment plans; an oral syrup should not be portrayed as an equivalent rescue inhaler. This ingredient profile does not constitute an approved Luang Pharma respiratory indication.
Clinical context and therapeutic role
Respiratory symptoms require a diagnosis and a written plan appropriate to asthma, chronic obstructive pulmonary disease or another condition. Bronchodilation can relieve narrowing of the airways, but salbutamol does not replace anti-inflammatory treatment when that is needed. Increasing reliance on a reliever or decreasing benefit can signal deterioration. Severe breathlessness, inability to speak normally, bluish coloration or exhaustion needs urgent care rather than repeated unsupervised use.
Selected safety context
Tremor, headache, palpitations and a faster heartbeat may occur. Excess exposure can cause dangerous heart rhythm problems and low potassium. Worsening wheeze immediately after inhalation may represent paradoxical bronchospasm and needs urgent review. Heart disease, thyroid disease, diabetes and interacting medicines should be considered. The prescribed device or formulation and its instructions must be followed. An oral product should never be substituted into a nebulizer or inhaler.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This is a proposed liquid oral presentation with a stated concentration. The liquid vehicle, sweeteners, preservatives and whether the medicine requires shaking must be verified from the final label. A liquid format does not, by itself, establish that all age groups are eligible.
Use the product’s appropriate calibrated oral measuring device and verify concentration each time a new bottle is supplied. Keep the cap and label intact. Follow the actual instructions for storage and any period after opening; do not transfer advice from another brand or concentration.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formula/specification identifying salbutamol base/salt expression.
Approved oral-product label/leaflet for the intended jurisdiction.
Container/closure and measuring-device specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Albuterol sulfate syrup 2 mg/5 mLArchived source classification: US official drug label example | Source revision recorded: Label updated 3 January 2025; Archived access check: 2026-09-11 | Comparator official label showing an oral albuterol/salbutamol syrup presentation; not Luang Pharma labelling or equivalence evidence. |
| MedlinePlus: AlbuterolArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-010.
Professional enquiries
Request product-specific evidence for LP-010.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.